Significance of treatment interval and DNA repair in the enhancement of viral transformation by chemical carcinogens and mutagens.
Treatment of Syrian hamster embryo cells with diverse classes of chemical carcinogens enhanced transformation by a carcinogenic simian adenovirus, SA7. Optimal enhancement was a function of time of chemical addition in relation to time of virus addition and cell transfer. Aflatoxin B1 (AFB1) and the polycyclic hydorcarbons, benzo(a)pyrene (B(a)P), 3-methylcholanthrene (MCA), and 7,12-dimethylbenz(a)anthracene (DMBA) enhanced SA7 transformation when added prior to virus, but inhibited transformation when added after virus absorption and cell transfer. The enhancement of SA7 transformation was maximal when cytosine arabinoside, caffeine and 6-acetoxy-benzo(a)pyrene (6-ac-B(a)P) were added after virus, but minimal when added before virus. A third class of chemicals, including beta-propiolactone (beta-PL), methyl methanesulfonate (MMS), N-acetoxy-2-acetylaminofluorene (Ac-AAF), N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), and methylazoxymethanol acetate (MAM-ac), enhanced SA7 transformation added before, or after, virus inoculation and cell transfer. All chemicals which induced changes in DNA sedimentation in alkaline sucrose gradients and unscheduled DNA (repair) synthesis in hamster cells, increased the frequency of SA7 transformation. However, several chemicals such as dibenz(a,h)anthracene (DB(a,h)A), benzo(e)pyrene (B(e)P), cytosine arabinoside, and caffeine enhanced SA7 transformation but did not induce DNA sedimentation changes or repair. Chemicals that cause DNA damage, which can be repaired by hamster cells, may enhance viral transformation by providing additional sites for integration of viral DNA during the repair process. Chemicals that apparently do not induce DNA repair synthesis may enhance viral transformation by incorporation of viral DNA into gaps in cell DNA at sites of unrepaired damage during scheduled DNA synthesis.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000494:pharmacology; D000099:Acetoxyacetylaminofluorene / Q000494:pharmacology; D000256:Adenoviridae / Q000378:metabolism; D000348:Aflatoxins / Q000494:pharmacology; D001580:Benzopyrenes / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D002273:Carcinogens / Q000494:pharmacology*; D002460:Cell Line; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D003561:Cytarabine / Q000494:pharmacology; D004260:DNA Repair / Q000187:drug effects*; D004261:DNA Replication / Q000187:drug effects; D008741:Methyl Methanesulfonate / Q000494:pharmacology; D008748:Methylcholanthrene / Q000494:pharmacology; D008769:Methylnitronitrosoguanidine / Q000494:pharmacology; D009153:Mutagens / Q000494:pharmacology*; D009858:Oncogenic Viruses / Q000378:metabolism; D011420:Propiolactone / Q000494:pharmacology
D000348:Aflatoxins; D001580:Benzopyrenes; D002273:Carcinogens; D009153:Mutagens; D003561:Cytarabine; D008769:Methylnitronitrosoguanidine; D002110:Caffeine; D008748:Methylcholanthrene; D015127:9,10-Dimethyl-1,2-benzanthracene; D000099:Acetoxyacetylaminofluorene; D011420:Propiolactone; D008741:Methyl Methanesulfonate